Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment.
Raul Dias Dos Santos FilhoAndrea RuzzaBei WangPaul MaruffAdrian SchembriAjay K BhatiaFrançois MachJean BergeronIsabelle GaudetJulie St PierreJohn J P KasteleinG Kees HovinghAlbert WiegmanDaniel GaudetFrederick J RaalPublished in: European journal of preventive cardiology (2023)
In paediatric patients with FH, 80 weeks of open-label evolocumab treatment had no negative impact on cognitive function.